75 related articles for article (PubMed ID: 1966858)
1. Retroviral vectors as vaccines and immunotherapeutics.
Jolly DJ; Warner JF
Semin Immunol; 1990 Sep; 2(5):329-39. PubMed ID: 1966858
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
3. Recombinant DNA virus vectors for vaccination.
Moss B
Semin Immunol; 1990 Sep; 2(5):317-27. PubMed ID: 2134016
[TBL] [Abstract][Full Text] [Related]
4. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients.
Stitz J; Steidl S; Merget-Millitzer H; König R; Müller P; Nocken F; Engelstädter M; Bobkova M; Schmitt I; Kurth R; Buchholz CJ; Cichutek K
Virology; 2000 Feb; 267(2):229-36. PubMed ID: 10662618
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.
Takeda J; Sato Y; Kiyosawa H; Mori T; Yokoya S; Irisawa A; Miyata M; Obara K; Fujita T; Suzuki T; Kasukawa R; Wanaka A
Cell Immunol; 2000 Aug; 204(1):11-8. PubMed ID: 11006013
[TBL] [Abstract][Full Text] [Related]
6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
7. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
8. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
[TBL] [Abstract][Full Text] [Related]
9. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
10. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
[TBL] [Abstract][Full Text] [Related]
11. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24.
Suzue K; Young RA
J Immunol; 1996 Jan; 156(2):873-9. PubMed ID: 8543845
[TBL] [Abstract][Full Text] [Related]
13. Anti-vector immunoglobulin induced by retroviral vectors.
McCormack JE; Martineau D; DePolo N; Maifert S; Akbarian L; Townsend K; Lee W; Irwin M; Sajjadi N; Jolly DJ; Warner J
Hum Gene Ther; 1997 Jul; 8(10):1263-73. PubMed ID: 9215743
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
15. Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine.
Hone DM; Lewis GK; Beier M; Harris A; McDaniels T; Fouts TR
Dev Biol Stand; 1994; 82():159-62. PubMed ID: 7958470
[TBL] [Abstract][Full Text] [Related]
16. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
17. Retroviral vector backbone immunogenicity: identification of cytotoxic T-cell epitopes in retroviral vector-packaging sequences.
Kondo E; Akatsuka Y; Nawa A; Kuzushima K; Tsujimura K; Tanimoto M; Kodera Y; Morishima Y; Kuzuya K; Takahashi T
Gene Ther; 2005 Feb; 12(3):252-8. PubMed ID: 15496958
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccination: antigen presentation and the induction of immunity.
Shedlock DJ; Weiner DB
J Leukoc Biol; 2000 Dec; 68(6):793-806. PubMed ID: 11129646
[TBL] [Abstract][Full Text] [Related]
19. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
20. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
[Next] [New Search]
